Prognostic heterogeneity in ASXL1-mutated AML and refinement by an immunophenotype-based score
{{output}}
Introduction: ASXL1 is a frequently mutated gene in acute myeloid leukemia (AML) and is clinically recognized as an adverse prognostic marker, yet its clinical impact remains markedly heterogeneous. ... ...
